Jacqualyn Fouse - Perrigo Company Independent Director

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:3em;padding-top: 40px;;'>PRG</div>
PRGO -- USA Stock  

0.225 Dividend

Ms. Jacqualyn A. Fouse is Independent Director of the Company. Ms. Fouse has served as President, President, Global Hematology Oncology of Celgene, a leading global biopharmaceutical company, since August 2014, and previously served as Executive Vice President and Chief Financial Officer from September 2010 to August 2014. From 2007 until September 2010, she served as Chief Financial Officer for Bunge Ltd., a leading global agribusiness and food company. From 2002 to 2007, Ms. Fouse served as Senior Vice President, Chief Financial Officer and Corporationrationrate Strategy, at Alcon Laboratories, a NYSElisted eye care company. Prior to that, Ms. Fouse was Chief Financial Officer of Swissair Group in Switzerland from 2001 to 2002, and she was Group Treasurer of Nestle S.A. in Switzerland from 1999 to 2001. Ms. Fouse previously held various senior level financial positions in both the U.S. and Switzerland with both Alcon and Nestle from 1986 to 1999. She also held positions with LTV Aerospace and Defense and Celanese Chemical Company from 1983 to 1986. Ms. Fouse has served on the Board of Dicks Sporting Goods, a leading U.S. retailer of sporting goods and athletic apparel, since September 2010 and in May 2013 was appointed Chair of the Audit Committee. Ms. Fouse also serves on the Development Board and the College of Business Administration Advisory Board of the University of Texas at Arlington and on the Advisory Board of Texas Christian University
Age: 54  Director Since 2012      
353 1 709 4000  http://www.perrigo.com

Jacqualyn Fouse Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 2.19 % which means that it generated profit of $2.19 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 4.32 % meaning that it created $4.32 on every $100 dollars invested by stockholders.
The company currently holds 3.5 B in liabilities with Debt to Equity (D/E) ratio of 60.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Perrigo Company has Current Ratio of 2.03 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Bruce SachsVertex Pharmaceuticals Incorpor
Robert ScullyZoetis
Louise ParentZoetis
Terrence KearneyVertex Pharmaceuticals Incorpor
Bharat DoshiDr Reddys Laboratories Ltd
Lloyd CarneyVertex Pharmaceuticals Incorpor
Michael BrownRegeneron Pharmaceuticals
Allan ObermanDr Reddys Laboratories Ltd
Shikha SharmaDr Reddys Laboratories Ltd
William SteereZoetis
Willie ReedZoetis
Margaret McGlynnVertex Pharmaceuticals Incorpor
Alfred GilmanRegeneron Pharmaceuticals
Sanjay KhoslaZoetis
Ashok GangulyDr Reddys Laboratories Ltd
Paul BisaroZoetis
Joseph GoldsteinRegeneron Pharmaceuticals
Yuchun LeeVertex Pharmaceuticals Incorpor
Larry CordellOrigin Agritech Limited
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
Huda ZoghbiRegeneron Pharmaceuticals

Company Summary

Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland. Perrigo Company operates under Drug ManufacturersSpecialty Generic classification in USA and is traded on BATS Exchange. It employs 10600 people.Perrigo Company Plc (PRGO) is traded on BATS Exchange in USA and employs 10,600 people.

Perrigo Company Leadership Team

John Hendrickson, PresidentView
Gary Cohen, Independent DirectorView
Arthur Shannon, IR Contact OfficerView
Ronald Winowiecki, Acting CFOView
Svend Andersen, Executive Vice President and President - Consumer Healthcare InternationalView
Judy Brown, CFO and Executive VPView
Laurie Brlas, Independent DirectorView
Donal OConnor, Independent DirectorView
James Michaud, Chief Human Resource Officer, Executive Vice PresidentView
Louis Yu, Executive Vice President - Global QualityView
John Wesolowski, Executive Vice President and Presidentident - RXView
Theodore Samuelsto, Independent DirectorView
Scott Jamison, Executive Vice President General Manager - NutritionalsView
Ellen Hoffing, Independent DirectorView
Marc Coucke, Executive Vice President General Manager - Omega Pharma BusinessView
Adriana Karaboutis, Independent DirectorView
Michael Jandernoa, Independent DirectorView
Paul Weninger, Executive Vice President - Global Quality OperationsView
Thomas Farrington, Senior Vice President CIOView
Herman Morris, Independent DirectorView
Jeffrey Needham, Executive Vice President General Manager - Consumer HealthcareView
Todd Kingma, Executive VP, General Counsel and SecretaryView
Rolf Classon, Independent DirectorView
Raymond Silcock, CFOView
Shlomo Yanai, Independent Director NomineeView
Jatin Shah, Senior Vice President Chief Scientific OfficerView
Michael Stewart, Senior Vice President - Global Human ResourcesView
Jeffrey Kindler, Independent DirectorView
Jacqualyn Fouse, Independent DirectorView
Grainne Quinn, Executive Vice President Chief Medical OfficerView
Theodore Samuels, Independent DirectorView
Geoffrey Parker, Independent DirectorView
Murray Kessler, President CEO, DirectorView
Sharon Kochan, Executive VP and General Manager of InternationalView
Gary Kunkle, Lead Independent DirectorView
Joseph Papa, Chairman and CEOView
Marry Brlas, Independent Chairman of the BoardView
Bradley Alford, Independent DirectorView
Jeffrey Smith, Independent DirectorView
Bradley Joseph, IR Contact OfficerView
James Dillard, Executive Vice President Chief Scientific OfficerView
Douglas Boothe, Executive Vice President General Manager - Rx PharmaceuticalsView
Ronald Janish, Executive Vice President - Global Operations and Supply ChainView
Uwe Rohrhoff, President CEO, DirectorView

Stock Performance Indicators

Current Sentiment - PRGO

Perrigo Company Investor Sentiment

Most of Macroaxis users are at this time bullish on Perrigo Company Plc. What is your perspective on investing in Perrigo Company Plc? Are you bullish or bearish?
98% Bullish
2% Bearish

Currently Active Assets on Macroaxis

Purchased over 100 shares of
a day ago
Traded for 30.71
Purchased over 500 shares of
a day ago
Traded for 3.54
Purchased over 100 shares of
a day ago
Traded for 30.71
Purchased over 40 shares of
a day ago
Traded for 66.38
Purchased over 70 shares of
a day ago
Traded for 43.18
Please check Your Equity Center. Please also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.